These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8782016)

  • 1. Virological markers of progression: a UK experience.
    Loveday C
    J Biol Regul Homeost Agents; 1995; 9(3):100-4. PubMed ID: 8782016
    [No Abstract]   [Full Text] [Related]  

  • 2. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
    Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
    Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival and disease progression in 251 patients with HIV-1 infection. Study of p24 antigen and viral burden as prognosis makers. Their value at 4 years of follow-up].
    Rubio Caballero M; Rubio Rivas C; Nogués Biau A; Falguera Sacrest M; Manonelles Fernández A
    An Med Interna; 2001 Oct; 18(10):517-20. PubMed ID: 11766280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focusing on the second phase of plasma HIV-1 RNA clearance.
    Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
    AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 10. Dynamics of HIV-1 viral load in pregnancy.
    Lillo FB; Bucceri AM; Bettini P; Farma E; Boeri E; Mastrorilli E; Rossi G; Vignali M; Varnier OE
    AIDS; 1997 Sep; 11(11):1397-8. PubMed ID: 9302452
    [No Abstract]   [Full Text] [Related]  

  • 11. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
    Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
    Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.